Effepharm is proud of its all-star R&D team. All the members are extremely experienced, most of whom came from top pharmaceutical companies like GSK, food companies like Mars Wrigley, and medicines and foods standard-setting organizations like USP.
We’re professional not only in the research, development, and process of manufacturing but also in the quality assurance of food ingredients. Our study covers lab testing, manufacturing, safety and efficacy research on animals and humans.
Our dedicated team of employees is passionate about helping the world with innovative technologies.
Director- Science & RA
Hank Hwang, a former scientist of USP, systematically researched the relationship of human body with drugs and foods during his research career at China Pharmaceutical University, Shanghai Jiaotong University and China State Institute of Pharmaceutical Industry. He joined USP in 2013, setting standards for medicines and foods which are applied worldwide. The standards include USP(United States Pharmacopeia), DSC(Dietary supplements compendium), FCC(Food chemical codex), etc.
With a strong pharmaceutical R&D background, Hank is responsible to incorporate modern pharmaceutical technology and higher medicine standards into the food ingredient industry, thus ensuring that Effepharm will provide food and pharmaceutical ingredients and services with the highest standard.
Under his direction, Effepharm is not only professional at process and manufacture, but also at quality, safety and efficacy of food ingredients.
Qinyuan Xu, master, is an extremely experienced scientist with 8 years of multiple production experience in 7 different pharmaceutical factories. His research mainly focuses on gene and antivirus drugs, including Pomalidomide, Gefitinib, Vidarabine Monophosphate, Butazodine, Escitalopram oxalate, Tiopronin, Prulifloxacin, Doxycycline Hydrochloride, Ritodrine hydrochloride, Pralidoxime Iodide, Fludarabine Phosphate, Etoposide, Gemcitabine Hydrochloride, Nelarabine, etc. Qinyuan helped Effepharm to solve different problems during some incredibly complicated production process and figured out ingenious solutions to cut down production cost.
Director of Business Development
Xiaojun Wang, who graduated from ECUST with a Master’s degree, published papers in top international Journal Angew. Chem. Int. Ed. (IF 12.102). Xiaojun was a former chain manager of Mars Wrigley. He took charge of standard operations, safety and quality management in packaging workshops as well as document management. Besides, he was also responsible for lean employees’ development and training. Xiaojun helps Effepharm to monitor the whole process to meet the cGMP requirements from raw materials to finished products.
Dr. Jian Hu
Jian Hu, Ph. D, graduated from East China University of Science and Technology, focusing on researches on small molecule catalysis and asymmetric synthesis. He participated in 3 NSFC(National Natural Science Foundation of China) projects. As first author, Dr. Hu has published 7 SCI papers in top Journals, such as J. Am. Chem Soc. (IF 14.357) Angew. Chem. Int. Ed.(IF 12.102). He also owns 4 published patents.
Dr. Hu has a deep understanding of catalysis and chiral induction with strong creativity. Dr. Hu joined new drug R&D center of GSK US headquarters(Philadelphia) to study antibiotic drugs in 2013. He participated in research of a world-first antibiotic drug and assisted with preclinical evaluation for many chemicals. He mainly took charge of designing and screening new active compound skeleton. He is professional at the process optimization of multi-step tandem reactions and the accurate preparation of chiral compounds. He has accumulated rich research, development and production experience in the design and preparation of macromolecular heterocyclic compounds, chiral separation and chiral induction.
Dr. Hu led his team to screen active ingredients at Effepharm, research their weakness and propose solutions, such as cutting-edge technology to cut down high production cost, extend the shelf life of some unstable products, IDS® platform to solve low bioavailability, mask spicy or bitter taste, etc.
Jianjun Yu, Ph. D, graduated from East China University of Science and Technology. Dr. Yu has published several SCI papers and applied for several patents.
He joined the new drug R&D center of GSK US (North Carolina) to study antivirus drugs in 2010. The long-acting anti-HIV new drug(Cabotegravir) he researched has now passed the second critical phase III clinical trial.
Dr. Yu returned to China and joined ECUST as a postdoctoral teacher to engage in teaching and scientific research.
As a core member of the team, the project he participated in got the 2019 science and technology progress award of the ministry of education.
Dr. Yu joined Effepharm to take charge of R&D in 2016, lots of best-selling products were launched since then.